Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/301% above fair value
$69.00−0.84 (-1.20%)
Close on Nov 13, 2026Market cap $16.84BP/E 20.7Yield –
Exelixis EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Exelixis's EPS for the twelve months ending Oct 2, 2026 was $3.34, up 40.9% year over year. For fiscal 2025 it was $2.78, up 58.0% from the year before. The highest annual figure on record is $2.78 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $2.78 | +58.0% |
| FY2024 | Jan 3, 2025 | $1.76 | +170.8% |
| FY2023 | Dec 29, 2023 | $0.65 | +16.1% |
| FY2022 | Dec 30, 2022 | $0.56 | -22.2% |
| FY2021 | Dec 31, 2021 | $0.72 | +105.7% |
| FY2020 | Jan 1, 2021 | $0.35 | -65.7% |
| FY2019 | Jan 3, 2020 | $1.02 | -53.8% |
| FY2018 | Dec 28, 2018 | $2.21 | +351.0% |
| FY2017 | Dec 29, 2017 | $0.49 | – |
| FY2016 | Dec 31, 2016 | -$0.28 | – |
| FY2015 | Dec 31, 2015 | -$0.77 | – |
| FY2014 | Dec 31, 2014 | -$1.34 | – |
| FY2013 | Dec 31, 2013 | -$1.29 | – |
| FY2012 | Dec 31, 2012 | -$0.91 | -256.9% |
| FY2011 | Dec 31, 2011 | $0.58 | – |
| FY2010 | Dec 31, 2010 | -$0.85 | – |
| FY2009 | Dec 31, 2009 | -$1.26 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Oct 2, 2026 | $0.85 | +23.2% |
| Q2 FY2026 | Jul 3, 2026 | $0.82 | +26.2% |
| Q1 FY2026 | Apr 3, 2026 | $0.79 | +43.6% |
| Q4 FY2025 | Jan 2, 2026 | $0.88 | +83.3% |
| Q3 FY2025 | Oct 3, 2025 | $0.69 | +72.5% |
| Q2 FY2025 | Jul 4, 2025 | $0.65 | -15.6% |
| Q1 FY2025 | Apr 4, 2025 | $0.55 | +358.3% |
| Q4 FY2024 | Jan 3, 2025 | $0.48 | +77.8% |
| Q3 FY2024 | Sep 27, 2024 | $0.40 | – |
| Q2 FY2024 | Jun 28, 2024 | $0.77 | +208.0% |
| Q1 FY2024 | Mar 29, 2024 | $0.12 | 0.0% |
| Q4 FY2023 | Dec 29, 2023 | $0.27 | – |
| Q3 FY2023 | Sep 29, 2023 | $0.00 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $0.25 | +13.6% |
| Q1 FY2023 | Mar 31, 2023 | $0.12 | -42.9% |
| Q4 FY2022 | Dec 30, 2022 | -$0.09 | -131.0% |
| Q3 FY2022 | Sep 30, 2022 | $0.23 | +91.7% |
| Q2 FY2022 | Jul 1, 2022 | $0.22 | -26.7% |
| Q1 FY2022 | Apr 1, 2022 | $0.21 | – |
| Q4 FY2021 | Dec 31, 2021 | $0.29 | +222.2% |
| Q3 FY2021 | Oct 1, 2021 | $0.12 | – |
| Q2 FY2021 | Jul 2, 2021 | $0.30 | +42.9% |
| Q1 FY2021 | Apr 2, 2021 | $0.00 | -100.0% |
| Q4 FY2020 | Jan 1, 2021 | $0.09 | -59.1% |
| Q3 FY2020 | Oct 2, 2020 | -$0.10 | -132.3% |
| Q2 FY2020 | Jul 3, 2020 | $0.21 | -16.0% |
| Q1 FY2020 | Apr 3, 2020 | $0.15 | -37.5% |
| Q4 FY2019 | Jan 3, 2020 | $0.22 | -80.9% |
| Q3 FY2019 | Sep 27, 2019 | $0.31 | -24.4% |
| Q2 FY2019 | Jun 28, 2019 | $0.25 | -10.7% |
| Q1 FY2019 | Mar 29, 2019 | $0.24 | -35.1% |
| Q4 FY2018 | Dec 28, 2018 | $1.15 | +858.3% |
| Q3 FY2018 | Sep 28, 2018 | $0.41 | +57.7% |
| Q2 FY2018 | Jun 29, 2018 | $0.28 | +366.7% |
| Q1 FY2018 | Mar 30, 2018 | $0.37 | +640.0% |
| Q4 FY2017 | Dec 29, 2017 | $0.12 | 0.0% |
| Q3 FY2017 | Sep 30, 2017 | $0.26 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.06 | – |
| Q1 FY2017 | Mar 31, 2017 | $0.05 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.12 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?